This aligns with the most recent European Conference on Infections in Leukaemia (ECIL)-10 guidelines, which recommend mold-active prophylaxis for AML patients experiencing prolonged neutropenia and mandate VEN dose adjustment when combined with moderate or strong CYP3A4 inhibitors [78]. The gene discussed is CYP3A4; the disease is acute myeloid leukemia.